An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial

Guidelines recommend effective on-demand therapy for all individuals with hereditary angioedema. We aimed to assess the novel oral plasma kallikrein inhibitor, sebetralstat, which is in development, for on-demand treatment of hereditary angioedema attacks. In this two-part phase 2 trial, individuals...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2023-02, Vol.401 (10375), p.458-469
Hauptverfasser:	Aygören-Pürsün, Emel, Zanichelli, Andrea, Cohn, Danny M, Cancian, Mauro, Hakl, Roman, Kinaciyan, Tamar, Magerl, Markus, Martinez-Saguer, Inmaculada, Stobiecki, Marcin, Farkas, Henriette, Kiani-Alikhan, Sorena, Grivcheva-Panovska, Vesna, Bernstein, Jonathan A, Li, H Henry, Longhurst, Hilary J, Audhya, Paul K, Smith, Michael D, Yea, Christopher M, Maetzel, Andreas, Lee, Daniel K, Feener, Edward P, Gower, Richard, Lumry, William R, Banerji, Aleena, Riedl, Marc A, Maurer, Marcus
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adverse events Angioedema Angioedemas, Hereditary - drug therapy Angioedemas, Hereditary - prevention & control Clinical trials Coronaviruses COVID-19 Cross-Over Studies Disease transmission Double-Blind Method Double-blind studies Drug dosages Edema Female Humans Inhibitors Kallikrein Kininogens Male Middle Aged Oral administration Permeability Pharmacodynamics Pharmacokinetics Pharmacology Placebos Plasma Plasma kallikrein Plasma Kallikrein - antagonists & inhibitors Safety Severe acute respiratory syndrome coronavirus 2 Teenagers Time of use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!